No quarterly revenue total was found in MapLight Therapeutics, Inc.'s SEC filings.
MapLight Therapeutics, Inc. (MPLT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$44.9 million. As of Jun 30, 2026 it held $351.3 million in cash and investments and $2.0 million in total debt.
Revenue
—
Net income
$-60.19M
+0.8% vs prior quarter
Operating cash flow
$-44.87M
+12.3% vs prior quarter
Free cash flow
$-44.89M
+12.3% vs prior quarter
EPS
$-1.32
+1.5% vs prior quarter
Dividend per share
None
Shares outstanding
45.44M
+0.5% vs prior quarter
Net cash
$349.35M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MPLT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1770069
- Former names
- Alvarado Therapeutics, Inc. (until Mar 22, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|
| Operating income | -$63.5M | -$64.5M | -$83.4M | -$31.5M |
| Net income | -$60.2M | -$60.7M | -$79.5M | -$29.4M |
| Diluted EPS | -$1.32 | -$1.34 | -$2.48 | -$37.18 |
| Operating cash flow | -$44.9M | -$51.2M | -$46.8M | -$91.3M |
| Free cash flow | -$44.9M | -$51.2M | -$47.2M | -$91.4M |
| Total assets | $368.3M | $418.8M | $479.5M | $257.2M |
| Total liabilities | $20.0M | $19.0M | $21.1M | $23.7M |
| Stockholders' equity | $348.3M | $399.8M | $458.4M | -$274.2M |
| Cash and investments | $351.3M | $395.2M | $453.1M | $227.2M |
| Total debt | $2.0M | $5.6M | $5.8M | $6.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Unregistered share sale, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 22, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 18, 2026 | Jun 18, 2026 |
All 209 MapLight Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.